TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25384473

Group type: EXPERIMENTAL
Intervention: Double-spinning platelet-enriched gel (PRP) with leukocytes
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Single-spinning platelet-rich preparation (PRGF Endoret® Technology) without leukocytes
Number of subjects: 150

Group type: COMPARATOR
Intervention: Non-gel group (control)
Number of subjects: 150
Study: 21859193

Group type: EXPERIMENTAL
Intervention: Positive appraisal training
Number of subjects: 0

Group type: COMPARATOR
Intervention: Negative appraisal training
Number of subjects: 0
Study: 20509875

Group type: EXPERIMENTAL
Intervention: n-3 polyunsaturated fatty acids (1 g daily)
Number of subjects: 12513

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12513
Study: 17885551

Group type: EXPERIMENTAL
Intervention: ACE inhibitor ramipril
Number of subjects: 347

Group type: EXPERIMENTAL
Intervention: Homozygous ACE haplotypes
Number of subjects: 347
Study: 16193341

Group type: EXPERIMENTAL
Intervention: 2 g L-carnitine
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 12114339

Group type: EXPERIMENTAL
Intervention: Rollator
Number of subjects: 40

Group type: COMPARATOR
Intervention: Unaided 6MWT
Number of subjects: 40
Study: 10434221

Group type: EXPERIMENTAL
Intervention: Dolasetron mesylate (12.5 mg, 25 mg, 50 mg, or 100 mg)
Number of subjects: 620

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 620
Study: 7599221

Group type: EXPERIMENTAL
Intervention: Coenzyme Q10 (100 mg daily for three months)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study: 2189951

Group type: EXPERIMENTAL
Intervention: Tamoxifen (40 mg daily) for 2 or 5 years
Number of subjects: 75

Group type: COMPARATOR
Intervention: Control (no adjuvant endocrine therapy)
Number of subjects: 75
Study: 708560

Group type: EXPERIMENTAL
Intervention: Three formulations of etomidate
Number of subjects: 0
Study: 30706508

Group type: EXPERIMENTAL
Intervention: Metronidazole (MTZ) 500 mg
Number of subjects: 16

Group type: COMPARATOR
Intervention: NIC gum 2 mg
Number of subjects: 16
Study: 27889366

Group type: EXPERIMENTAL
Intervention: Intranasal lidocaine
Number of subjects: 162

Group type: COMPARATOR
Intervention: Saline solution (Control)
Number of subjects: 162
Study: 26356396

Group type: EXPERIMENTAL
Intervention: L-lysine aescinat
Number of subjects: 40

Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 40
Study: 23256139

Group type: EXPERIMENTAL
Intervention: VA-fortified milk (250 mL daily providing 196 retinol equivalents/d) for 3 months
Number of subjects: 27
Study: 21277984

Group type: EXPERIMENTAL
Intervention: Naloxone (0.15 mg/kg)
Number of subjects: 62

Group type: COMPARATOR
Intervention: NaCl (0.9%)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Placebo-mediated suggestion
Number of subjects: 62
Study: 19343439

Group type: EXPERIMENTAL
Intervention: High BMI group (BMI >= 25 kg/m²)
Number of subjects: 1485

Group type: COMPARATOR
Intervention: Low BMI group (BMI < 25 kg/m²)
Number of subjects: 1485
Study: 17409404

Group type: EXPERIMENTAL
Intervention: Bortezomib
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cluster 1 (high expression of cancer testis antigen and proliferation‐associated genes)
Number of subjects: 0
Study: 15567009

Group type: EXPERIMENTAL
Intervention: Prophylactic ibuprofen
Number of subjects: 135

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 135
Study: 11515891

Group type: EXPERIMENTAL
Intervention: Active monitoring of infection control practices (149 practices) in the operating room and intensive care unit
Number of subjects: 106
Study: 9576071

Group type: EXPERIMENTAL
Intervention: Eversion CEA
Number of subjects: 1353

Group type: COMPARATOR
Intervention: Standard CEA
Number of subjects: 1353
Study: 7936830

Group type: EXPERIMENTAL
Intervention: Adherent Escherichia coli isolates from NEC cases
Number of subjects: 17

Group type: COMPARATOR
Intervention: Adherent Escherichia coli isolates from control infants
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Coinfection with Gram-positive isolates from control children
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Coinfection with Gram-positive isolates from NEC cases
Number of subjects: 17
Study: 3340287

Group type: EXPERIMENTAL
Intervention: Alprazolam
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 29759104

Group type: EXPERIMENTAL
Intervention: High-fat meal with mainly SFA (40 E%)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: High-fat meal with mainly PUFA (40 E%)
Number of subjects: 27
Study: 28132005

Group type: EXPERIMENTAL
Intervention: Low energy shock wave therapy plus eccentric exercises
Number of subjects: 93

Group type: COMPARATOR
Intervention: Placebo treatment plus eccentric exercises
Number of subjects: 93
Study: 26573453

Group type: EXPERIMENTAL
Intervention: Kinesio taping
Number of subjects: 41

Group type: COMPARATOR
Intervention: Sham taping
Number of subjects: 41
Study: 23946609

Group type: EXPERIMENTAL
Intervention: Milligan‐Morgan hemorrhoidectomy with anal cushion suspension and partial internal sphincter resection
Number of subjects: 192

Group type: COMPARATOR
Intervention: Traditional external dissection and internal ligation
Number of subjects: 192
Study: 21167351

Group type: EXPERIMENTAL
Intervention: Left Radial Approach (LRA)
Number of subjects: 1540

Group type: COMPARATOR
Intervention: Right Radial Approach (RRA)
Number of subjects: 1540
Study: 19342358

Group type: EXPERIMENTAL
Intervention: Parental involvement in HIV/AIDS preventive education (IG2)
Number of subjects: 339

Group type: EXPERIMENTAL
Intervention: Nurses alone (IG1)
Number of subjects: 339

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 339
Study: 16686958

Group type: EXPERIMENTAL
Intervention: Low-dose Cisplatin, 5-Fluorouracil and Interferon alpha with external beam radiation
Number of subjects: 1
Study: 14967870

Group type: EXPERIMENTAL
Intervention: High-fat/moderate protein diet (HFMP; 61% fat)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (C; 25% fat)
Number of subjects: 20
Study: 10928433

Group type: COMPARATOR
Intervention: 0.75% ropivacaine alone
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 0.75% ropivacaine plus fentanyl 1 microg kg(‐1)
Number of subjects: 30
Study: 8657239

Group type: EXPERIMENTAL
Intervention: Immunoblot assay for KSHV antigens
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Immunoblot assay over a period of 13 to 103 months
Number of subjects: 40
Study: 1423954

Group type: EXPERIMENTAL
Intervention: Internal cardioversion with 200-300-J shocks
Number of subjects: 112

Group type: COMPARATOR
Intervention: External cardioversion with 300-360-J shocks
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Internal cardioversion
Number of subjects: 112

Group type: COMPARATOR
Intervention: External cardioversion
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Amiodarone therapy
Number of subjects: 112
Study: 2935094

Group type: EXPERIMENTAL
Intervention: IV bolus of 10.0‐50.0 U/h according to glycosuria (Group A)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Continuous IV insulin infusion of 2.5 U/h (Group B)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Continuous IV insulin infusion of 5.0 U/h (Group C)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Continuous IV insulin infusion of 7.5 U/h (Group D)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Continuous IV insulin infusion of 10.0 U/h (Group E)
Number of subjects: 24

Group type: COMPARATOR
Intervention: No insulin given (Non-diabetic patients - NDP)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Continuous IV insulin infusion of 2.5 U/h in a patient with advanced chronic renal failure (CRF)
Number of subjects: 24
Study: 31479947

Group type: EXPERIMENTAL
Intervention: Adjuvant imatinib treatment
Number of subjects: 908
Study: 30315600

Group type: EXPERIMENTAL
Intervention: Baitfish purchased from retail dealers
Number of subjects: 5400
Study: 27029654

Group type: EXPERIMENTAL
Intervention: ProSealTM laryngeal mask airway (PLMA)
Number of subjects: 44

Group type: COMPARATOR
Intervention: ClassicTM laryngeal mask airway (CLMA)
Number of subjects: 44
Study: 24852204

Group type: EXPERIMENTAL
Intervention: LESS-P (mini-laparoscopic-assisted LESS pyeloplasty)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: LESS-PN (mini-laparoscopic-assisted LESS partial nephrectomy)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: LESS-RP (mini-laparoscopic-assisted LESS radical prostatectomy)
Number of subjects: 30
Study: 22510472

Group type: EXPERIMENTAL
Intervention: Group education at their homes (House Calls)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Group-Based education in the transplant center
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Individual Counseling in the transplant center
Number of subjects: 180
Study: 19176186

Group type: EXPERIMENTAL
Intervention: Rigid ankle-foot orthosis (R-AFO)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Dynamic ankle-foot orthosis (D-AFO)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Barefoot walking
Number of subjects: 11
Study: 17224716

Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 58

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study: 16084762

Group type: EXPERIMENTAL
Intervention: Levosimendan
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Prostaglandin E1 (PGE1)
Number of subjects: 73
Study: 12780979

Group type: EXPERIMENTAL
Intervention: Intravenous salbutamol (15 &micro;g/kg)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 84
Study: 10734512

Group type: EXPERIMENTAL
Intervention: Perfloxacin 400 mg bd twice a day for five days
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Ofloxacin 200 mg bd twice a day for five days
Number of subjects: 60
Study: 7859136

Group type: EXPERIMENTAL
Intervention: Atovaquone
Number of subjects: 0

Group type: COMPARATOR
Intervention: TMP-SMX
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pentamidine
Number of subjects: 0
Study: 1954153

Group type: EXPERIMENTAL
Intervention: Toluene at 150 ppm
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Ethanol at 0.66 g EtOH/kg body weight
Number of subjects: 42

Group type: COMPARATOR
Intervention: Toluene at 150 ppm (EtOH equivalents)
Number of subjects: 42
Study: 6941640

Group type: EXPERIMENTAL
Intervention: alpha‐beta‐blocker (labetalol 300 mg b.d.)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: alpha‐beta‐blocker (propranolol 80 mg b.d.)
Number of subjects: 10

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 10
Study: 31318721

Group type: EXPERIMENTAL
Intervention: Targeted postgraduate education on optic disc assessment
Number of subjects: 46

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 46
Study: 28465550

Group type: EXPERIMENTAL
Intervention: Chloroquine (CQ)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 79
Study: 25715366

Group type: EXPERIMENTAL
Intervention: Ultrasound treatment
Number of subjects: 357

Group type: COMPARATOR
Intervention: Conventional medical treatment (Control)
Number of subjects: 357
Study: 25173535

Group type: EXPERIMENTAL
Intervention: Biodegradable polymer sirolimus-eluting stents (SES)
Number of subjects: 2119

Group type: COMPARATOR
Intervention: Durable polymer everolimus-eluting stents (EES)
Number of subjects: 2119
Study: 23079671

Group type: EXPERIMENTAL
Intervention: Ad‐ECRG2 (adenoviral vector)
Number of subjects: 0
Study: 19583069

Group type: EXPERIMENTAL
Intervention: Closed arterial blood gas sampling and pediatric vials for phlebotomy (Group A)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Standard technique of arterial line sampling and adult vial phlebotomy (Group B)
Number of subjects: 39
Study: 17631737

Group type: EXPERIMENTAL
Intervention: Laser therapy and stretching exercises (LSG, n=10)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Stretching exercises only (SG, n=10)
Number of subjects: 20
Study: 15801574

Group type: EXPERIMENTAL
Intervention: Contingent vouchers for biochemically verified smoking abstinence
Number of subjects: 58

Group type: COMPARATOR
Intervention: Noncontingent vouchers earned independent of smoking status
Number of subjects: 58
Study: 12413614

Group type: EXPERIMENTAL
Intervention: Cyclic transdermal 17‐beta estradiol (0.10 mg/day, Climara)
Number of subjects: 132

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 132
Study: 9636847

Group type: EXPERIMENTAL
Intervention: Granulocyte-macrophage colony-stimulating factor (GM-CSF)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Granulocyte colony-stimulating factor (G-CSF)
Number of subjects: 0
Study: 8593018

Group type: EXPERIMENTAL
Intervention: Isepamicin 7.5 mg/kg once daily for 10 days
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Isepamicin 7.5 mg/kg twice daily for 10 days
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Isepamicin 15 mg/kg once daily for 10 days
Number of subjects: 18
Study: 2649123

Group type: EXPERIMENTAL
Intervention: Extradural 0.5% bupivacaine with additional morphine (bolus 4 mg plus 0.5 mg h‐1)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Extradural 0.5% bupivacaine without morphine
Number of subjects: 22
Study: 367851

Group type: EXPERIMENTAL
Intervention: Levamisole (2.5 mg/kg body weight on 2 consecutive days/week for 3 months)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 29052236

Group type: COMPARATOR
Intervention: Conventional ICD programming (Arm A)
Number of subjects: 1500

Group type: EXPERIMENTAL
Intervention: High-rate cut-off ICD programming (Arm B)
Number of subjects: 1500

Group type: EXPERIMENTAL
Intervention: Delayed therapy ICD programming (Arm C)
Number of subjects: 1500
Study: 26458923

Group type: EXPERIMENTAL
Intervention: Adapted Physical Activity (APA) program (aerobic and resistance exercises) in addition to usual care (including chemotherapy at the investigator's choice)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Usual care (including chemotherapy at the investigator's choice)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Adapted Physical Activity (APA) program
Number of subjects: 200
Study: 22985217

Group type: EXPERIMENTAL
Intervention: Selenium
Number of subjects: 312

Group type: EXPERIMENTAL
Intervention: Vitamin E
Number of subjects: 312
Study: 21288144

Group type: EXPERIMENTAL
Intervention: Alprazolam 0.5 mg
Number of subjects: 53

Group type: COMPARATOR
Intervention: Captopril 25 mg
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Both groups (Alprazolam and Captopril)
Number of subjects: 53
Study: 19219907

Group type: EXPERIMENTAL
Intervention: Newly developed compound for the treatment of osteoarthritis and rheumatoid arthritis
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 18551937

Group type: EXPERIMENTAL
Intervention: Intramuscular injection of botulinum toxin type‐A (BTX‐A)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study: 15588742

Group type: EXPERIMENTAL
Intervention: Intravenous magnesium sulphate infusion
Number of subjects: 6213

Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 6213

Group type: EXPERIMENTAL
Intervention: Region 2 patients (Bulgaria, Georgia, and Russia)
Number of subjects: 6213

Group type: EXPERIMENTAL
Intervention: Region 1 patients (United States and Canada)
Number of subjects: 6213

Group type: EXPERIMENTAL
Intervention: Region 3 patients (Austria, Belgium, Chile, Hungary, Israel, the Netherlands, New Zealand, and Venezuela)
Number of subjects: 6213
Study: 11165203

Group type: EXPERIMENTAL
Intervention: Presence of the C allele of the AT(1) gene in hypertensive subjects with hypercholesterolemia
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Overall population with hypercholesterolemia
Number of subjects: 131

Group type: COMPARATOR
Intervention: Hypertensive subjects
Number of subjects: 131
Study: 9018020

Group type: EXPERIMENTAL
Intervention: tianeptine (25-50 mg/day)
Number of subjects: 126

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 126
Study: 8361865

Group type: COMPARATOR
Intervention: Hyperbaric oxygen (HBO)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Normobaric oxygen (NBO)
Number of subjects: 5
Study: 3007605

Group type: EXPERIMENTAL
Intervention: Captopril (100 mg orally)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: HOE 498 (10 mg orally)
Number of subjects: 6
Study: 30545333

Group type: EXPERIMENTAL
Intervention: Intensive treatment of the mother including psychotherapy and pharmacotherapy (Step 1 treatment group)
Number of subjects: 143

Group type: COMPARATOR
Intervention: Supportive counseling only for mother (Step 1 control group)
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Parent-child training (PCT) (Step 2 for both TG and CG)
Number of subjects: 143
Study: 27515756

Group type: EXPERIMENTAL
Intervention: Social Stories intervention
Number of subjects: 50

Group type: COMPARATOR
Intervention: Waiting list control group
Number of subjects: 50
Study: 23920353

Group type: EXPERIMENTAL
Intervention: Online behavioural weight management (OBWM) intervention
Number of subjects: 572

Group type: COMPARATOR
Intervention: Online basic lifestyle information (OBLI) intervention
Number of subjects: 572

Group type: EXPERIMENTAL
Intervention: OBLI+BEV (fortified diet cola beverage)
Number of subjects: 572

Group type: EXPERIMENTAL
Intervention: OBWM+BEV (fortified diet cola beverage)
Number of subjects: 572

Group type: EXPERIMENTAL
Intervention: OBWM condition
Number of subjects: 572
Study: 22174429

Group type: EXPERIMENTAL
Intervention: Fingolimod 0.5 mg
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Fingolimod 1.25 mg
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study: 20868962

Group type: EXPERIMENTAL
Intervention: 0.03 mg/kg neostigmine
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 0.05 mg/kg neostigmine
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control (spontaneous recovery)
Number of subjects: 60
Study: 18037627

Group type: EXPERIMENTAL
Intervention: Everolimus (6 mg/day)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 121
Study: 12061620

Group type: EXPERIMENTAL
Intervention: Children instructed to keep play activities secret
Number of subjects: 48

Group type: COMPARATOR
Intervention: Children not instructed to keep play activities secret
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Highly suggestive interview questions
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Less suggestive interview questions
Number of subjects: 48
Study: 10530104

Group type: EXPERIMENTAL
Intervention: Toothpaste containing 10% carbamide peroxide (DW)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Toothpaste containing 3% hydrogen peroxide (HP)
Number of subjects: 30
Study: 8091384

Group type: EXPERIMENTAL
Intervention: Fibrinogen
Number of subjects: 516

Group type: EXPERIMENTAL
Intervention: D-Dimer
Number of subjects: 516

Group type: EXPERIMENTAL
Intervention: Thrombin-Antithrombin complexes
Number of subjects: 516
Study: 2577377

Group type: EXPERIMENTAL
Intervention: Ebastine (10 mg daily escalating to 40 mg daily)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Ebastine
Number of subjects: 40
Study: 1103017

Group type: EXPERIMENTAL
Intervention: S‐Adenosylmethionine (25 mg i.m. three times daily)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Imipramine (25 mg i.m. three times daily)
Number of subjects: 31
Study: 28296725

Group type: EXPERIMENTAL
Intervention: Pregabalin
Number of subjects: 535

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 535
Study: 25244562

Group type: EXPERIMENTAL
Intervention: Standardized 60-min prevention lesson focusing on preventable risk factors for headache and providing instructions on stress management and neck and shoulder muscle relaxation exercises.
Number of subjects: 900

Group type: COMPARATOR
Intervention: Control group (no intervention).
Number of subjects: 900

Group type: EXPERIMENTAL
Intervention: Intervention group (standardized lesson).
Number of subjects: 900
Study: 24073667

Group type: EXPERIMENTAL
Intervention: MUP group (n = 34)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Control group (n = 35)
Number of subjects: 69
Study: 21320119

Group type: EXPERIMENTAL
Intervention: Levetiracetam (up to 30 mg/kg/day)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study: 19229821

Group type: EXPERIMENTAL
Intervention: Oral vitamin D3 1,000 IU/day
Number of subjects: 128

Group type: COMPARATOR
Intervention: Control (no vitamin D3 supplementation)
Number of subjects: 128
Study: 16881778

Group type: EXPERIMENTAL
Intervention: Group psychotherapy
Number of subjects: 325
Study: 15701212

Group type: EXPERIMENTAL
Intervention: Olopatadine 0.1% ophthalmic solution
Number of subjects: 68

Group type: COMPARATOR
Intervention: Levocabastine 0.05% ophthalmic suspension
Number of subjects: 68
Study: 11257665

Group type: EXPERIMENTAL
Intervention: Local anesthesia
Number of subjects: 73

Group type: COMPARATOR
Intervention: Epidural anesthesia
Number of subjects: 73
Study: 9212965

Group type: EXPERIMENTAL
Intervention: Pulsatile flow mode of Terumo Capiox centrifugal pump
Number of subjects: 11

Group type: COMPARATOR
Intervention: Intraaortic balloon pumping (IABP)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Pulsatile mode of the 3M Delphin pump
Number of subjects: 11

Group type: COMPARATOR
Intervention: Nonpulsatile CPB
Number of subjects: 11
Study: 8426198

Group type: EXPERIMENTAL
Intervention: Recent treatment protocols (H1, H2, H5)
Number of subjects: 1082

Group type: EXPERIMENTAL
Intervention: Salvage treatment
Number of subjects: 1082

Group type: COMPARATOR
Intervention: Late relapsing patients
Number of subjects: 1082
Study: 3304382

Group type: EXPERIMENTAL
Intervention: Calcitonin (i.v. 1.5 i.u. kg‐1 body mass bolus or 10 i.u. followed by infusion to overall 1.5 i.u. kg‐1 body mass dose)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 31752829

Group type: EXPERIMENTAL
Intervention: BV juice (480 ml/day)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Placebo (480 ml/day)
Number of subjects: 85
Study: 28472058

Group type: EXPERIMENTAL
Intervention: Poractant alfa
Number of subjects: 87

Group type: COMPARATOR
Intervention: Bovine lipid extract surfactant
Number of subjects: 87
Study: 25928562

Group type: EXPERIMENTAL
Intervention: Intervention (school-based curriculum, out-of-school outreach, community mobilisation, health-worker training in youth-friendly health services)
Number of subjects: 2664

Group type: COMPARATOR
Intervention: Comparison (community mobilisation and youth-friendly health services training only)
Number of subjects: 2664